Bio-Thera Solutions (SHSE:688177) Debt-to-Equity : 0.70 (As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Bio-Thera Solutions Debt-to-Equity?

Bio-Thera Solutions's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was ¥338.2 Mil. Bio-Thera Solutions's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was ¥349.1 Mil. Bio-Thera Solutions's Total Stockholders Equity for the quarter that ended in Jun. 2024 was ¥975.8 Mil. Bio-Thera Solutions's debt to equity for the quarter that ended in Jun. 2024 was 0.70.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Bio-Thera Solutions's Debt-to-Equity or its related term are showing as below:

SHSE:688177' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.03 Max: 0.7
Current: 0.7

During the past 8 years, the highest Debt-to-Equity Ratio of Bio-Thera Solutions was 0.70. The lowest was 0.00. And the median was 0.03.

SHSE:688177's Debt-to-Equity is ranked worse than
81.09% of 1047 companies
in the Biotechnology industry
Industry Median: 0.14 vs SHSE:688177: 0.70

Bio-Thera Solutions Debt-to-Equity Historical Data

The historical data trend for Bio-Thera Solutions's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Thera Solutions Debt-to-Equity Chart

Bio-Thera Solutions Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.16

0.02

0.01

0.40

Bio-Thera Solutions Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Debt-to-Equity	Get a 7-Day Free Trial															0.21	0.38	0.40	0.54	0.70

Competitive Comparison of Bio-Thera Solutions's Debt-to-Equity

For the Biotechnology subindustry, Bio-Thera Solutions's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bio-Thera Solutions's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bio-Thera Solutions's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Bio-Thera Solutions's Debt-to-Equity falls into.

Bio-Thera Solutions Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Bio-Thera Solutions's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(158.787	+	323.835)	/	1212.715
	=	0.40

Bio-Thera Solutions's Debt to Equity Ratio for the quarter that ended in Jun. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(338.237	+	349.116)	/	975.826
	=	0.70

Bio-Thera Solutions (SHSE:688177) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Bio-Thera Solutions Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Bio-Thera Solutions's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Bio-Thera Solutions Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Thera Solutions Ltd (SHSE:688177) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

5th Floor, Building A6, 11 Kaiyuan Avenue, Guangzhou High-tech Industrial Development Zone, Science City, Guangdong Province, Guangzhou, CHN, 510530

Website

https://www.bio-thera.com

Bio-Thera Solutions Ltd is engaged in research, development, and production of drugs and biosimilars. The company provides drug research and development; biotechnology consulting and communication services; services; medical research and experimental development; biological drug manufacturing; and pharmaceuticals retail.

Bio-Thera Solutions Headlines

No Headlines